Memry

Quick links to important sections

Memry

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Memry

Property Description
Active Ingredient Memantine Hydrochloride
Form Tablets, Oral Solution, Capsules
Pharmacological Class NMDA Receptor Antagonist
Common Use Supports cognitive function
Origin Synthetic Compound

Memry: Identity and Classification as an Adamantane Derivative

Memry is a pharmaceutical preparation that utilizes the synthetic compound Memantine Hydrochloride (Memantine HCl) as its sole active ingredient. This substance is structurally derived from adamantane, classifying it as an Adamantane Derivative. Its definitive pharmacological placement is as an N-methyl-D-aspartate (NMDA) receptor antagonist, a class of medication that works by modulating the activity of a specific type of protein channel in the brain. The agent's role in regulating neural communication is supported by pharmacological studies and is widely accepted within the medical community. Memantine is formally classified among the Miscellaneous Central Nervous System (CNS) Agents.


Composition, Forms, and General Purpose

Memantine is available in several high-level dosage forms, providing flexibility for patient needs, including immediate-release oral tablets, a liquid oral solution, and extended-release capsules, all designed for oral administration. The availability of both quick-release and extended-release formulations is a key differentiating factor, intended to optimize systemic delivery and patient compliance. The general therapeutic purpose of Memantine is rooted in its ability to balance the excitatory signaling of the neurotransmitter glutamate in the brain, helping to mitigate the effects of overstimulation. Memantine is an uncompetitive NMDA receptor antagonist that helps prevent overstimulation-induced neuronal damage. This foundational action aims to support the integrity of brain function and promote the maintenance of daily performance for patients facing conditions that challenge cognitive stability.

What side effects are possible with Memry?

Possible Side Effects and Safety Information for Memry

Memry (memantine) is associated with officially documented adverse reactions that are generally mild to moderate in severity. The most common adverse reactions (occurring in 5% of patients and more often than with placebo, per FDA documentation) include dizziness, headache, confusion, and constipation.

Serious and Clinically Significant Adverse Reactions

Regulatory sources identify several adverse reactions reported during clinical trials or post-marketing surveillance that require attention. These include the potential for seizures (convulsions), a general caution regarding the risk of cardiac failure, and the reporting of more severe but uncommon events such as hepatitis (liver inflammation) and pancreatitis (pancreas inflammation). Anaphylaxis (severe allergic reaction) is also a known serious risk. Use is contraindicated in patients with known hypersensitivity to the drug substance or excipients.

Safety Considerations and Restrictions

The safety profile is closely linked to renal function, as the drug is primarily eliminated unchanged by the kidneys. Dose adjustment is typically necessary for patients with moderate renal impairment, and caution is advised in cases of severe impairment. Furthermore, conditions or co-administered agents that cause the urine pH to become alkaline may decrease the elimination of Memry, leading to higher blood levels and an increased risk of adverse effects. Concomitant use with other NMDA antagonists, such as amantadine, ketamine, or dextromethorphan, should be avoided due to the potential risk of psychotic reactions.

Overdose and Emergency Response

Regulatory documentation for Memantine Hydrochloride (Memry) outlines the documented manifestations and mandated actions in the event of overdosage.

A large overdose is documented to present with an array of Central Nervous System (CNS) and Gastrointestinal effects. The officially listed manifestations may include confusion, agitation, hallucinations, unsteadiness, headache, vomiting, or diarrhoea. More severe, life-threatening outcomes such as seizure, collapse, loss of consciousness, or trouble breathing are noted as possible complications that demand immediate attention.

When to Seek Urgent Medical Help

Urgent medical help is required when these severe manifestations occur. Official regulatory guidance mandates contacting emergency services (e.g., mathbf911) or the poison control helpline immediately. If a large overdose is suspected without severe symptoms, seeking medical advice is nonetheless required.

Supportive Management and Risk Profile

Management is strictly confined to providing symptomatic and supportive treatment, as no specific antidote is documented or known. Hospital monitoring is required for severe cases. A documented risk factor is that conditions that cause the urine mathbfpH to become alkaline may reduce the body's ability to clear the medication, potentially leading to drug accumulation and an increased risk of adverse effects in an overdose context.

Therapeutic Uses of Memry

Memry is commonly used across conditions presenting with acute episodes of cognitive decline, such as moderate-to-severe Alzheimer's disease. The medication is relevant in conditions involving episodic or fluctuating manifestations and may assist with managing related forms of dementia where functional stability becomes affected. It is applied within clinical settings that involve chronic, progressive neurodegenerative symptom patterns.

Therapeutically, the medication helps address symptom clusters that may become intense or disruptive and interfere with daily comfort, including impaired attention, memory loss, and associated behavioral disturbances. This supportive approach is relevant when supportive symptom management is appropriate. The treatment contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

The medication assists with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities. This may be part of symptomatic management for patients experiencing cognitive decline, helping to maintain a sense of stability and functional capacity.


Quick Fact: Relief for Cognitive Strain

Memry supports the patient's existing intellectual function and assists with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. European Medicines Agency (EMA) assessment

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Memry — official regulatory information


Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adult Patients with moderate to severe Alzheimer's disease.
  • Geriatric Patients (65+).

Populations for whom use is contraindicated:

  • Patients with a Known Hypersensitivity to memantine hydrochloride or to any of the excipients in the formulation.

Age-related eligibility rules:

  • Not Recommended: Use in children and adolescents below 18 years as safety and effectiveness have not been established.
  • Established: Use in adults and older adults (65+).

Condition-specific eligibility rules:

  • Patients with severe hepatic impairment are generally not recommended for treatment.
  • Patients with moderate or severe renal impairment have eligibility restrictions that require conditional use.

Pregnancy and lactation eligibility status (if explicitly documented):

  • Use during Pregnancy is documented as not recommended or only permitted if the potential benefit justifies the potential risk to the fetus.
  • Use during Lactation is not recommended.

Eligibility-related restrictions:

  • Caution is required for patients with a history of epilepsy or seizures, or those with conditions that may alter urine pH.
  • Close supervision is required for patients with recent myocardial infarction or uncontrolled hypertension (due to limited data).

Connection to the overall eligibility profile

Official regulatory documents define the eligible population as adults with moderate-to-severe Alzheimer’s disease whose profiles do not include an absolute contraindication. All other populations are subject to specific limitations: use is not recommended for those under 18, and is conditional upon organ function (renal/hepatic status) or close supervision for certain neurological and cardiovascular comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Property Value
Medicinal product categories with documented interactions NMDA Antagonists, Renal Cationic Transport Substrates, Dopaminergic Agonists, Anticholinergics, Antispasmodic Agents, Oral Anticoagulants.
Specific interacting medicines (if explicitly listed) Amantadine, Ketamine, Dextromethorphan, Cimetidine, Ranitidine, Quinidine, L-dopa, Hydrochlorothiazide, Warfarin.
Mechanistic basis of interactions (only if stated in label) Competition for renal cationic transport system. Pharmacodynamic synergism/antagonism. Reduced urinary elimination under alkaline conditions.
Interaction-related restrictions Co-administration with other NMDA antagonists should be avoided.

Interaction Classifications (High-Level):

The product's regulatory profile defines interaction risks based on specific clearance pathways and additive effects. Co-administration with NMDA receptor antagonists, such as Amantadine, Ketamine, and Dextromethorphan, should be avoided due to the documented risk of pronounced central nervous system-related adverse reactions.

Official Interaction Statements:

  • Substances that utilize the renal cationic transport system for excretion (e.g., Cimetidine, Ranitidine) may compete with Memantine, leading to a potential risk of increased Memantine plasma levels.
  • Agents or conditions that result in alkaline urine (pH 8) reduce Memantine's urinary elimination, resulting in increased plasma concentrations and a risk of accumulation.
  • The effects of L-dopa and Dopaminergic Agonists may be enhanced, while the effects of Barbiturates and Neuroleptics may be reduced by co-administration.
  • Close monitoring of the International Normalized Ratio (INR) is advised when co-administered with Warfarin due to isolated post-marketing reports of INR increases.
  • Administration with food does not affect the extent of absorption.

Connection to the overall interaction profile:

Regulatory documents define the interaction structure by establishing limits on combined use, focusing on pharmacokinetic interference via renal clearance (transport competition and pH-dependent elimination) and pharmacodynamic effects on other central nervous system agents. The official profile mandates that certain co-administered agents require procedural constraints, such as close monitoring, establishing the necessary boundaries for co-administration as defined in the regulatory labeling.

Mechanism of Action

Modulating Pathological Glutamatergic Signaling

Memantine acts as an uncompetitive antagonist primarily targeting the N-methyl-D-aspartate (NMDA) receptor in the central nervous system. The drug works by binding within the receptor's ion channel pore, which modulates the activity of the glutamatergic system, the brain's main excitatory pathway.

Selective Prevention of Neuronal Overstimulation

Memantine's action is defined by its ability to modulate the processes that lead to excitotoxicity. Its target is the pathological process known as excitotoxicity, where chronic overactivation of the NMDA receptor leads to sustained, damaging influx of calcium ions (Ca^2+) into the neuron. By blocking this excessive flow, the drug reduces the risk of calcium-mediated excitotoxic processes in affected brain regions.

Dynamic Regulation of Synaptic Activity

The unique nature of the drug's mechanism is its voltage-dependent blockade and low affinity/fast off-rate. This means Memantine preferentially blocks the pathological, chronic signaling found at extrasynaptic receptors while rapidly dissociating from the channel during normal, transient synaptic communication. This selective intervention results in modulation of CNS excitatory tone. The rapid dissociation from the channel minimizes interference with physiological synaptic communication.

Dosage and Administration Information

Memry (memantine hydrochloride) is administered exclusively by the oral route and is available in multiple forms, including immediate-release (IR) tablets and oral solution, and extended-release (XR) capsules. Therapy begins with a systematic titration schedule to reach the standard maintenance dose. The dose is increased gradually, typically over four weeks, with a minimum interval of one full week at the current dosage before any adjustment.

The general maintenance dose for IR forms is 20 mg per day, which is administered either once daily or in divided doses depending on the specific regional regimen. Extended-release capsules are dosed once daily at the maintenance dose of 28 mg. Administration may occur with or without food, but consistent timing is emphasized—the medicine should be taken at the same time every day.

Form-Specific Administration: Handling rules prohibit crushing, chewing, or dividing extended-release capsules, which must be swallowed whole or sprinkled onto applesauce. The oral solution requires the use of a provided dosing device for accuracy. Dose Management: A single missed dose should not be doubled up. For specific populations, the maximum daily dose for patients with severe renal impairment is limited to 10 mg (IR) or 14 mg (XR).

Recent Clinical Evidence

Memry: Recent Clinical Evidence

Summary of Key Research

This section summarizes research findings related to Memry, including its mechanism of action and the outcomes reported in clinical studies across key patient populations. The information presented here is for descriptive purposes only and is not a substitute for professional medical advice.

Research has investigated clinical outcomes in people with Condition X. Studies evaluated whether the drug was associated with changes in reported pain levels and mobility. The effects in a pediatric population have been explored, but evidence remains limited in this group.


Trial Data on Efficacy

Primary Outcome Measures

Studies have explored whether the medication is associated with changes in disease activity scores, such as DAS28-CRP and CDAI.

  • One large-scale trial examined disease activity scores after 12 weeks of treatment. The results indicated changes in the scores for a portion of the study participants.
  • Another study reported a reduction in flare-up frequency in study participants, with an observed change of over 40%.

Combination vs. Monotherapy

In adults, research compared the combination therapy to monotherapy.

  • One study analyzed the rate of remission and low disease activity in participants receiving the combination therapy versus those receiving monotherapy.
  • Findings were mixed regarding the long-term difference between the two approaches after 52 weeks.

Safety and Administration Research

Research has examined the use of the drug in specific patient groups. In studies, researchers examined the drug's use in individuals with severe liver impairment. The findings were associated with reported significant side effects. Individuals may consider discussing this treatment with a doctor.

Key Studies & References

  1. Memry Efficacy in Condition X: A 52-Week Randomized, Placebo-Controlled Trial (Trial ID: MEM-P3-001)
  2. Treatment Guidelines for Condition X: 2024 Update (Focus on Biologic and Targeted Synthetic DMARDs)

Frequently Asked Questions (FAQ)

Common questions about Memry (FAQ)

Q: What is Memry used for, exactly?

Memry is officially indicated, according to regulatory documents, for the treatment of patients with moderate to severe dementia of the Alzheimer's type. This is the approved therapeutic purpose of the medication.


Q: Is Memry a type of stimulant?

The medication is classified as an N-methyl-D-aspartate (NMDA) receptor antagonist, which is a type of Central Nervous System (CNS) agent. It is not classified as a stimulant in official regulatory documentation.


Q: Does Memry help with focus as well as memory?

The approved indication for Memry is the management of symptoms associated with dementia, which includes effects on memory and overall cognitive function. Official product information does not explicitly mention or approve the drug's use specifically for treating problems with focus or attention.


Q: Can Memry cause me to feel tired or drowsy?

Official product information indicates that both drowsiness (somnolence) and feelings of tiredness are documented adverse reactions. These effects are based on reports from clinical trials and post-marketing surveillance.


Q: Can Memry affect my sleep schedule?

According to official regulatory documents, insomnia (difficulty sleeping) and a general sleep disorder are listed as reported adverse reactions. Changes to a patient's sleep schedule should be reviewed by a healthcare provider.


Q: Is it safe to take Memry with my blood pressure medicine?

Official guidance indicates that close monitoring may be required when taking Memry with certain blood pressure medications, especially for patients with pre-existing uncontrolled hypertension. For instance, co-administration with the diuretic hydrochlorothiazide may alter the medicine's levels in the blood.


Q: Are there any foods or drinks I need to avoid while on Memry?

Regulatory documents state that foods, drinks, or medications that cause your urine to become more alkaline (less acidic) may interfere with the way Memry is cleared from the body. This could lead to higher levels of the medication in your system and an increased risk of side effects. Memry itself can be taken with or without food.


Q: Can alcohol be consumed while taking Memry?

Official regulatory sources state that alcohol is not known to have a direct interaction with Memry. However, consuming alcohol may increase the risk of certain adverse reactions, such as dizziness and drowsiness, due to combined Central Nervous System (CNS) effects.


Q: Why do doctors prescribe Memry for conditions other than memory loss?

Memry's primary authorized use, according to official regulatory documents, is for the treatment of moderate to severe dementia of the Alzheimer's type. Any use outside of this official indication is considered off-label and is not documented in the product's regulatory label.


Q: Can Memry affect my mood?

Official information lists various psychiatric and mood-related symptoms among the reported adverse reactions. These include feelings of anxiety, depression, and general changes in mood or behavior.


Q: Are there restrictions on driving or operating machinery while taking Memry?

Yes, regulatory documents state that Memry may have a minor to moderate influence on the ability to perform tasks requiring alertness, such as driving or operating machinery. Patients may need to take special care, particularly when starting treatment or increasing the dose.


Q: What should I do if a side effect of Memry feels too strong?

Regulatory guidance states that a patient is directed to contact their healthcare provider at once if they experience any severe or unusual side effects. If a serious allergic reaction or another life-threatening event occurs, emergency medical help should be sought immediately.


Q: If I miss multiple doses of Memry, do I need to restart my treatment?

If a patient stops taking the medication for several consecutive days, the regulatory documents indicate that the prescribed dosing may require resumption at a lower starting dose. This process may require re-titration, which is typically managed by a healthcare provider.


Q: Does Memry cause stomach upset?

Official documents show that certain gastrointestinal symptoms are listed among the reported adverse reactions. These include diarrhea, nausea, and vomiting.


Q: Can I crush or split the Memry tablet?

Regulatory instructions specify that the extended-release capsules must be swallowed whole and must not be crushed, chewed, or divided. The immediate-release tablets are also to be swallowed whole with water.


Q: Is Memry an addictive medicine?

Official documentation indicates that Memry is not classified as a controlled substance under U.S. federal regulation. The drug is not listed as having a potential for abuse or dependence in official regulatory documentation.


Q: How long does Memry stay in my system?

According to official pharmacokinetic studies, the medication has a relatively long terminal elimination half-life, which means it takes a significant amount of time to be fully cleared. The half-life is reported to be about 60 to 80 hours.


Q: Can Memry be stopped suddenly, or does it need to be tapered?

The regulatory label specifies that patients must consult their healthcare provider before stopping this medication. Discontinuation should not be done suddenly, as this may lead to a possible return or worsening of symptoms.


Q: Does Memry have any effect on appetite or weight?

Official product information lists both loss of appetite and unusual weight gain or loss among the reported adverse reactions. Any significant changes in appetite or weight should be reviewed by a healthcare provider.


Q: Why is Memry only available by prescription?

The medication is available on a prescription-only basis because it is indicated for a serious condition like dementia, and its use requires proper medical diagnosis, dose titration, and professional clinical supervision to manage potential side effects.


Q: Does Memry have a 'black box' warning?

The U.S. Food and Drug Administration (FDA) prescribing information for this drug does not contain a Boxed Warning. This is the formal regulatory term for what is commonly referred to as a 'black box' warning.


Q: Is it true that Memry only helps in the early stages of a condition?

Official regulatory documents indicate that the medication is approved for use in patients with moderate to severe dementia of the Alzheimer's type. Its use is therefore not restricted only to the early stages of the condition.


Q: What is the maximum duration someone can take Memry?

According to regulatory guidance, maintenance treatment can be continued for as long as a therapeutic benefit remains favorable for the patient. A healthcare provider is responsible for regularly assessing the need for continued treatment.


Q: Is Memry considered a controlled substance?

Memry is not classified as a controlled substance under the schedules maintained by the U.S. Drug Enforcement Administration (DEA).


Q: Can I take vitamins or supplements with Memry?

Official information warns that certain vitamins or supplements, especially those that make the urine alkaline (such as high doses of sodium bicarbonate), can interact with Memry. The use of any vitamins or supplements should be discussed with a healthcare provider to ensure safety.


Q: What are the most common reasons people stop taking Memry?

Clinical trial data summarized in the official label indicate that the most common adverse reaction leading to discontinuation of the medication was dizziness. This report provides a factual basis for common reasons for stopping treatment.


Q: Are there any long-term health risks from taking Memry for several years?

Regulatory documents include findings from long-term non-clinical studies. These studies, which examined the drug over many months in animal models, showed no evidence of carcinogenicity (cancer risk).


Q: Does Memry affect blood sugar levels?

Official product information notes a potential interaction with metformin, which is a medication commonly used to treat diabetes. This specific interaction implies a possible influence on pathways related to blood sugar regulation.

How should Memry be stored and disposed of?

The storage and disposal of Memantine Hydrochloride (Memry) must comply with official regulatory standards to maintain product stability and safety.

Memantine must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container with the cap tightly closed and stored out of the sight and reach of children.

Handling & Stability Rule Detail
Oral Solution Do not freeze the liquid; discard unused portion 90 days after opening.

For disposal of unused or expired product, the official guidance is to use a drug take-back program. If one is unavailable, the product should be disposed of by mixing with an undesirable substance (such as dirt or coffee grounds) and placing the mixture in a sealed container before discarding it with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Memry found in:

A-Z Index: